ArticleArthritis research & therapy2025
Mechanical growth factor inhibited syndesmophyte formation and the progression of osteoarthritis and ankylosing spondylitis-like symptoms in HLA-B27/Hu-β2m transgenic rats.
Article in Arthritis research & therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The role of exosomes in ankylosing spondylitis: from biological features and functional cargo to clinical applications.Frontiers in molecular biosciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundStudies have documented that exercise programs have symptomatic relief benefits for ankylosing spondylitis patients. It has also been reported that MGF (Mechanical/Mechano Growth Factor) and related gene expressions can be stimulated by certain exercises. In this study, we explored the possible role(s) MGF could play in controlling arthritis and ankylosing spondylitis-like symptoms in HLA-B27/Hu-β2m transgenic rats.
methodsHLA-B27/ Hu-β2m transgenic rats were inoculated with inactivated Mycobacterium tuberculosis to induce arthritis and ankylosing spondylitis, followed by MGF treatment for seven weeks. The animal models were monitored for the onset, severity, and progression of clinical symptoms.
resultsOur results indicated a dose-dependent increase in the time of onset of arthritis symptoms from 14 days in the control group to 23 days in the high-dose MGF group. Our results also indicated a dose-dependent increase in the anti-inflammatory cytokines IL-2 and IL-10 and decrease in the pro-inflammatory cytokine TNF-α in the peripheral circulation and in bony infiltrations. Likewise, there was a dose-dependent inhibition of STAT3 (signal transducer and activator of transcription 3) and RORγt (retinoic acid-related orphan receptor gamma-t) expression, which was further confirmed by the inhibition of IL-17 expression.
conclusionFrom the results of our study, it can be concluded that MGF controlled inflammation and inhibited bone erosion and syndesmophyte formation in HLA-B27/Hu-β2m transgenic rats by stimulating IL-2 and IL10 production while downregulating TNF-α, STAT3, RORγt, and IL-17 expression in a dose-dependent manner, leading to a significant reduction in arthritis and AS-like clinical symptoms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.